Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease.

Jaszberenyi M, Rick FG, Szalontay L, Block NL, Zarandi M, Cai RZ, Schally AV.

Aging (Albany NY). 2012 Nov;4(11):755-67.

2.

Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology.

Isopi E, Granzotto A, Corona C, Bomba M, Ciavardelli D, Curcio M, Canzoniero LM, Navarra R, Lattanzio R, Piantelli M, Sensi SL.

Neurobiol Dis. 2015 Sep;81:214-24. doi: 10.1016/j.nbd.2014.11.013.

PMID:
25434488
3.

Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid-β in an APP transgenic mouse model.

Liao F, Zhang TJ, Mahan TE, Jiang H, Holtzman DM.

Brain Behav Immun. 2015 Jul;47:163-71. doi: 10.1016/j.bbi.2014.09.005.

4.

Neuroprotective Potential of Novel Multi-Targeted Isoalloxazine Derivatives in Rodent Models of Alzheimer's Disease Through Activation of Canonical Wnt/β-Catenin Signalling Pathway.

Machhi J, Sinha A, Patel P, Kanhed AM, Upadhyay P, Tripathi A, Parikh ZS, Chruvattil R, Pillai PP, Gupta S, Patel K, Giridhar R, Yadav MR.

Neurotox Res. 2016 May;29(4):495-513. doi: 10.1007/s12640-016-9598-4.

PMID:
26797524
5.

Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.

Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Busto R, Halmos G.

J Clin Endocrinol Metab. 2001 May;86(5):2144-52.

PMID:
11344219
6.

Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.

Klukovits A, Schally AV, Szalontay L, Vidaurre I, Papadia A, Zarandi M, Varga JL, Block NL, Halmos G.

Cancer. 2012 Feb 1;118(3):670-80. doi: 10.1002/cncr.26291.

7.

Neuroprotective Effects of Icariin on Brain Metabolism, Mitochondrial Functions, and Cognition in Triple-Transgenic Alzheimer's Disease Mice.

Chen YJ, Zheng HY, Huang XX, Han SX, Zhang DS, Ni JZ, He XY.

CNS Neurosci Ther. 2016 Jan;22(1):63-73. doi: 10.1111/cns.12473.

PMID:
26584824
8.

Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.

Szalontay L, Schally AV, Popovics P, Vidaurre I, Krishan A, Zarandi M, Cai RZ, Klukovits A, Block NL, Rick FG.

Cell Cycle. 2014;13(17):2790-7. doi: 10.4161/15384101.2015.945879.

10.

Growth hormone releasing hormone (GHRH) signaling modulates intermittent hypoxia-induced oxidative stress and cognitive deficits in mouse.

Nair D, Ramesh V, Li RC, Schally AV, Gozal D.

J Neurochem. 2013 Nov;127(4):531-40. doi: 10.1111/jnc.12360.

11.

Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI).

Kanashiro-Takeuchi RM, Takeuchi LM, Rick FG, Dulce R, Treuer AV, Florea V, Rodrigues CO, Paulino EC, Hatzistergos KE, Selem SM, Gonzalez DR, Block NL, Schally AV, Hare JM.

Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):559-63. doi: 10.1073/pnas.1119203109.

12.

Loss of endophilin-B1 exacerbates Alzheimer's disease pathology.

Wang DB, Kinoshita Y, Kinoshita C, Uo T, Sopher BL, Cudaback E, Keene CD, Bilousova T, Gylys K, Case A, Jayadev S, Wang HG, Garden GA, Morrison RS.

Brain. 2015 Jul;138(Pt 7):2005-19. doi: 10.1093/brain/awv128.

13.

Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.

Keller G, Schally AV, Groot K, Toller GL, Havt A, Köster F, Armatis P, Halmos G, Zarandi M, Varga JL, Engel JB.

Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10628-33.

14.

Neuroprotective Role of Novel Triazine Derivatives by Activating Wnt/β Catenin Signaling Pathway in Rodent Models of Alzheimer's Disease.

Sinha A, Tamboli RS, Seth B, Kanhed AM, Tiwari SK, Agarwal S, Nair S, Giridhar R, Chaturvedi RK, Yadav MR.

Mol Neurobiol. 2015 Aug;52(1):638-52. doi: 10.1007/s12035-014-8899-y.

PMID:
25257697
15.

AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.

Fisher A, Brandeis R, Bar-Ner RH, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):145-53.

PMID:
12212772
16.

Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease.

Pedersen WA, McCullers D, Culmsee C, Haughey NJ, Herman JP, Mattson MP.

Neurobiol Dis. 2001 Jun;8(3):492-503.

PMID:
11442356
18.

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.

Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick FG.

Oncotarget. 2012 Sep;3(9):988-97.

19.

L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.

Peng Y, Sun J, Hon S, Nylander AN, Xia W, Feng Y, Wang X, Lemere CA.

J Neurosci. 2010 Jun 16;30(24):8180-9. doi: 10.1523/JNEUROSCI.0340-10.2010.

20.

Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology.

Hao W, Liu Y, Liu S, Walter S, Grimm MO, Kiliaan AJ, Penke B, Hartmann T, Rübe CE, Menger MD, Fassbender K.

Brain. 2011 Jan;134(Pt 1):278-92. doi: 10.1093/brain/awq325.

PMID:
21115468

Supplemental Content

Support Center